Clovis Oncology, Inc. (CLVS)

Lifshitz & Miller announces investigation on behalf of CLVS investors concerning whether CLVS adequately disclosed test data for rociletinib, CLVS' lung cancer drug.

If you are a CLVS investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at


821 Franklin Avenue

Suite 209

Garden City, NY 11530

Office: (516) 493-9780

Fax: (516) 280-7376


​​​​© 2020 by Lifshitz Law Firm, P.C. All rights reserved. | Sitemap | Disclaimer | Proudly created with

  • Grey Facebook Icon
  • Grey Twitter Icon
  • Grey LinkedIn Icon